Skip to Main content Skip to Navigation
Journal articles

Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

C. Lebrun S. Vukusic 1 V. Abadie C. Achour F. Ader 2 H. Alchaar A. Alkhedr F. Andreux 3 G. Androdias R. Arjmand B. Audoin 4 D. Audry D. Aufauvre C. Autreaux X. Ayrignac 5 M. Bailbe M. Benazet C. Bensa D. Bensmail E. Berger P. Bernady Y. Bertagna D. Biotti A. Blanchard-Dauphin J. Bonenfant 6 M. Bonnan B. Bonnemain F. Borgel E. Botelho-Nevers 7 S. Boucly B. Bourre C. Boutière 8 P. Branger D. Brassat 4 S. Bresch 9 V. Breuil 10 B. Brochet 4 H. Brugeilles P. Bugnon P. Cabre J.-P. Camdessanché C. Carra-Dalière O. Casez J.-M. Chamouard B. Chassande P. Chataignier M. Chbicheb A. Chenet 11 J. Ciron P. Clavelou 4 M. Cohen 12 R. Colamarino N. Collongues 4 I. Coman P.-R. Corail S. Courtois M. Coustans 13 A. Créange 14 E. Creisson N. Daluzeau C. Davenas J. de Seze 4 M. Debouverie 15 R. Depaz N. Derache L. Divio X. Douay C. Dulau F. Durand-Dubief 16 G. Edan 13 Z. Elias O. Fagniez M. Faucher 17 J.-M. Faucheux M. Fournier 18 A. Gagneux-Brunon 7 P. Gaida P. Galli P. Gallien J. Gaudelus 19 D. Gault 20 A. Gayou M. Genevray A. Gentil J. Gere L. Gignoux M. Giroux P. Givron O. Gout 21 J. Grimaud A.-M. Guennoc N. Hadhoum P. Hautecoeur O. Heinzlef M. Jaeger 22 S. Jeannin L. Kremer 23 A. Kwiatkowski P. Labauge 4 C. Labeyrie S. Lachaud I. Laffont 24 C. Lanctin-Garcia J. Lannoy L. Lanotte D. Laplaud 25 D. Latombe M. Lauxerois E. Le Page 6 C. Lebrun-Frenay 26 P. Lejeune P. Lejoyeux B. Lemonnier Emmanuelle Leray 27, 28, 29 C.-M. Loche C. Louapre 30 C. Lubetzki 31 A. Maarouf 4 B. Mada L. Magy 4 E. Maillart 32 E. Manchon R. Marignier 33 P. Marque G. Mathey 15 A. Maurousset C. Mekies M. Merienne 23 L. Michel 34 A.-M. Milor X. Moisset 35 A. Montcuquet T. Moreau N. Morel M. Moussa J.-P. Naudillon M. Normand P. Olive J.-C. Ouallet O. Outteryck C. Pacault C. Papeix 32 I. Patry 36 D. Peaureaux J. Pelletier 37 B. Pichon 38 S. Pittion E. Planque M.-C. Pouget V. Pourcher 39 C. Radot I. Robert F. Rocher A. Ruet 40 C. Saint-Val J.-Y. Salle A. Salmon E. Sartori S. Schaeffer B. Stankhof F. Taithe 41 E. Thouvenot 4 C. Tizon A. Tourbah 42 P. Tourniaire M. Vaillant 43 P. Vermersch 4 S. Vidil A. Wahab M.-H. Warter S. Wiertlewski 44 B. Wiplosz B. Wittwer C. Zaenker H. Zephir 4
16 RMN et optique : De la mesure au biomarqueur
CREATIS - Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé
Abstract : Objectives: To establish recommendations on immunization for patients with multiple sclerosis (MS).Background: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have been raised more recently about an increased risk of infection or a decreased effectiveness of immunization in immunosuppressed patients.Methods: The French Group for Recommendations into Multiple Sclerosis (France4MS) performed a systematic search of papers in Medline and other university databases (January 1975-June 2018). The RAND/UCLA appropriateness method was chosen to review the scientific literature and to formalize the degree of agreement among experts on 5 clinical questions related to immunization and MS. Readers from the steering committee conducted a systematic analysis, wrote a critical synthesis and prepared a list of proposals that were evaluated by a rating group of 28 MS experts. The final version of the recommendations was finally reviewed by a reading group of 110 health care professionals and classified as appropriate, inappropriate or uncertain.Results: Neurologists should verify the vaccination status as soon as MS is diagnosed and before disease-modifying treatments (DMTs) are introduced. The French vaccination schedule applies to MS patients and seasonal influenza vaccination is recommended. In the case of treatment-induced immunosuppression, MS patients should be informed about the risk of infection and the vaccination standards of the French High Council of Health should be applied. Live attenuated vaccines are contra-indicated in patients recently treated with immunosuppressive drugs, including corticosteroids; other vaccines can be proposed whatever the treatment, but their effectiveness may be partly reduced with some drugs.Conclusion: Physicians and patients should be aware of the updated recommendations for immunizations of patients with MS.
Document type :
Journal articles
Complete list of metadatas

https://hal.ehesp.fr/hal-02546158
Contributor : Scd Ehesp <>
Submitted on : Friday, April 17, 2020 - 5:14:19 PM
Last modification on : Wednesday, September 23, 2020 - 4:38:26 AM

Identifiers

Citation

C. Lebrun, S. Vukusic, V. Abadie, C. Achour, F. Ader, et al.. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Revue Neurologique, Elsevier Masson, 2019, 175 (6), pp.341-357. ⟨10.1016/j.neurol.2019.04.001⟩. ⟨hal-02546158⟩

Share

Metrics